Cerebrolysin

Stroke · 2025

Researchers studied the effects of combining speech therapy with a treatment called Cerebrolysin in patients recovering from nonfluent aphasia after a stroke. They found that this combination led to greater improvements in language function and neurological deficits compared to speech therapy alone, highlighting the potential benefits of additional therapies in stroke recovery.

• The combination of Cerebrolysin and speech therapy resulted in significant improvements in language function as measured by the Western Aphasia Battery.
• Participants receiving Cerebrolysin showed more substantial reductions in neurological deficits compared to those receiving a placebo.
• Overall, both treatment groups improved over time, but the Cerebrolysin group experienced greater enhancements in recovery.

Frontiers in pharmacology · 2024

Researchers conducted a comprehensive analysis of various neuroprotective drugs used in patients with acute ischemic stroke. They found that certain treatments, particularly ginkgolide and edaravone, were associated with lower mortality rates and better recovery outcomes compared to standard care.

• Researchers observed that ginkgolide, edaravone, and cinepazide maleate significantly reduced mortality rates in patients with acute ischemic stroke.
• The analysis ranked ginkgolide, edaravone, and edaravone dexborneol as the safest and most effective treatments based on their effectiveness and side effects.
• Researchers found that most neuroprotective agents improved neural function compared to standard treatment, with citicoline and vinpocetine showing the highest efficacy.

The Cochrane database of systematic reviews · 2023

Researchers studied the effects of Cerebrolysin, a peptide mixture derived from pig brain, on patients with acute ischaemic stroke. They found that Cerebrolysin likely does not reduce the risk of death and may be associated with an increase in non-fatal serious adverse events.

• Cerebrolysin probably has little to no effect on reducing all-cause death in acute ischaemic stroke patients.
• There is moderate evidence suggesting that Cerebrolysin may lead to an increase in non-fatal serious adverse events.
• The study indicated no significant difference in the total number of serious adverse events between those receiving Cerebrolysin and those receiving placebo.

The Cochrane database of systematic reviews · 2020

Researchers studied the effects of Cerebrolysin, a peptide mixture derived from pig brain, on patients with acute ischaemic stroke. They found that Cerebrolysin likely has little to no impact on reducing overall death rates or serious adverse events compared to placebo, while there may be an increase in non-fatal serious adverse events.

• Cerebrolysin probably results in little to no difference in all-cause death rates among stroke patients.
• There is likely no significant difference in the total number of serious adverse events between those treated with Cerebrolysin and those given a placebo.
• The study suggests a potential increase in non-fatal serious adverse events associated with Cerebrolysin use.

The Cochrane database of systematic reviews · 2019

Researchers studied the effects of Cerebrolysin, a brain-derived treatment, on cognitive function and overall well-being in people with vascular dementia. They found some evidence suggesting improvements in cognition and global function, but the overall quality of the evidence was very low, indicating that more robust studies are needed.

• Researchers observed a beneficial effect of Cerebrolysin on cognitive function based on data from three studies.
• The study indicated improvements in global function, with participants showing better outcomes on specific assessments.
• However, the evidence was limited and of very low quality, highlighting the need for more rigorous research.

The Cochrane database of systematic reviews · 2017

Researchers studied the effects of cerebrolysin, a mixture of peptides from pig brain tissue, on patients with acute ischaemic stroke. They found no significant clinical benefits from cerebrolysin compared to placebo, although there was an increase in non-fatal serious adverse events associated with its use.

• There was no difference in the number of deaths between patients receiving cerebrolysin and those receiving a placebo.
• Researchers observed an increase in non-fatal serious adverse events in the cerebrolysin group compared to the placebo group.
• Overall, the study did not demonstrate any clinical benefits of cerebrolysin for treating acute ischaemic stroke.

The Cochrane database of systematic reviews · 2015

Researchers studied the effects of Cerebrolysin, a mixture of peptides from pig brain tissue, on patients with acute ischaemic stroke. The analysis found no significant differences in death rates or adverse events between those receiving Cerebrolysin and those receiving a placebo, indicating that routine use of this treatment cannot be supported by current evidence.

• Researchers found no difference in death rates between patients treated with Cerebrolysin and those given a placebo.
• The total number of adverse events was similar in both the Cerebrolysin and placebo groups.
• The evidence from the analyzed trial does not support the routine use of Cerebrolysin for acute ischaemic stroke.

The Cochrane database of systematic reviews · 2013

Researchers studied the effects of Cerebrolysin on cognitive function in elderly patients with vascular dementia. They found that Cerebrolysin may improve general cognitive abilities and overall clinical function, although the evidence is not strong enough to recommend it as a standard treatment.

• Cerebrolysin showed a beneficial effect on cognitive function as measured by standard assessments.
• The treatment also improved global clinical function in participants.
• Only non-serious side effects were reported, with no significant difference in side effects between treatment and control groups.

Journal of neural transmission (Vienna, Austria : 1996) · 2000

Researchers studied the effects of FPF-1070 (Cerebrolysin) on nerve growth in chicken embryo neurons. They found that FPF-1070 promoted nerve growth in certain types of neurons but was less effective than nerve growth factor. The study also revealed that FPF-1070 had no impact on another type of neuron, indicating its effects vary by neuron type.

• FPF-1070 significantly promoted neurite outgrowth in dorsal root ganglia and sympathetic trunk neurons.
• The effectiveness of FPF-1070 showed an inverted U relationship with concentration in these neurons.
• FPF-1070 did not affect neurite outgrowth in ciliary ganglia neurons, which responded well to another growth factor.

No to shinkei = Brain and nerve · 1993

Researchers studied the effects of cerebrolysin (FPF 1070), a brain extract, on protecting neurons in gerbils after a temporary loss of blood flow to the brain. They found that administering cerebrolysin before the ischemic event significantly protected brain cells, while giving it afterward did not show the same benefits.

• Cerebrolysin provided significant protection to CA1 neurons when given 2 hours before blood flow was restricted.
• No protective effects were observed when cerebrolysin was administered immediately after blood flow was restored.
• The study indicated that cerebrolysin may help reduce harmful hydroxyl radicals produced in the brain after ischemia.